COVID-19: Our series of regulatory legislation trackers for the Life Sciences & Healthcare industry

Regulatory 1 min
May 7, 2020

COVID-19 presents an unprecedented challenge to the global life sciences industry.  Members of our International Life Sciences & Healthcare team, lawyers who have a wealth of hands-on experience and strong relationships with regulatory bodies, have worked together to provide an update in the form of a Q&A for each of the countries we are located.  This update aims to provide guidance on the responses of EU and Asia-Pac regulators in the areas of clinical trials, medical devices, market access, public procurement and compulsory licensing.

Today we release the latest in our series, focusing on Public Procurement, watch this space for the others coming very soon!

  • COVID-19: Legislation Tracker for Medical Devices, read here
  • COVID-19: Legislation Tracker for Clinical Trials, read here
  • COVID-19: Legislation Tracker for Public Procurement, read here
  • COVID-19: Legislation Tracker for State Use/Compulsory Licensing, read here

Related articles

Post-Transition Brexit: New MHRA Guidelines on Medicines
With a post-transition Brexit looming on the horizon, the Medicines and Healthcare products Regulatory...
Final(ly) Rules of Procedure of the UPC
Apart from the Unified Patent Court Agreement and a large body of further treaties, regulations,...